Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) has provided a corporate update on its barium and iodine contrast media projects, emphasizing its strategy to address supply chain vulnerabilities in the diagnostic imaging sector. The global contrast media market is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's approach involves creating a secure, vertically integrated supply chain encompassing mineral discovery through finished product manufacturing.
The company is advancing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek (FC) barium project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical-grade barium sulfate, with average purity of 98.8% BaSO4, exceeding the Pharmaceutical Grade threshold of 97.5%. Voyageur has completed product development for five Health Canada-approved barium products in collaboration with Alberta Veterinary Laboratories, generating approximately C$32,000 in initial sales. These sales and pricing data are being incorporated into the FC BFS, which is expected to be delivered in the second half of 2026.
On the regulatory front, Voyageur has commenced the FDA approval process for its barium products via the 505(b)(2) pathway, with submission documents drafted and formal initiation in February 2026. The FDA is expected to provide pending requirements in Q1 2026, with a review process anticipated to take 18 to 24 months, potentially enabling U.S. market entry as soon as mid-2027 to late 2027. The company also plans to advance a generic iodine FDA license in the second half of 2026.
Voyageur is independently advancing a prefeasibility study for iodine contrast media drug production, integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. This project targets 35 million doses per year, leveraging iodine-rich brine from U.S. oil and gas operations. The Bayer Iodine Project, supported by a US$2.35 million funding arrangement, focuses on completing a BFS. Under a potential second phase, Bayer would provide capital financing while Voyageur operates the project, with all intellectual property owned by Voyageur.
The company is engaging a global engineering firm to complete the final BFS for both projects. Upon completion, Voyageur will have finalized economics and plant design to become the only vertically integrated radiology drug company, producing from earth to bottle. The company is actively reviewing financing options for CAPEX, targeting construction to commence in 2027.
